SynAct Pharma partners with Örebro University to study cardiovascular disease
SynAct Pharma partners with Örebro University to study cardiovascular disease Publicerad: 12 maj 2021 13:37 Uppdaterad: 12 maj 2021 13:37 SynAct Pharma AB ("SynAct") today announced the company is a partner in a research project at Örebro University to study the reduction of inflammation in vascular disease. Dela på Facebook Uppdaterad: 12 maj 2021 13:37 The study, named “Targeting the melanocortin system as a novel strategy to reduce inflammation during vascular disease,” will be led Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The study i...